Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia
2022-502049-91-00Phase 2Suspended
- Sponsor
- Eagle Pharmaceuticals
- Start
- Jun 2023
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in community acquired pneumonia (CAP) comparing CAL02 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Time to clinical recovery, Incidence and severity of treatment-emergent adverse events and 1 more. Started Jun 2023; status: suspended.
02
Drugs
CAL02
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2022-502049-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502049-91-00.